Setmelanotide for the Treatment of Early-Onset POMC Deficiency Obesity
Status:
Completed
Trial end date:
2020-07-16
Target enrollment:
Participant gender:
Summary
The purpose of the study is to determine the effect of setmelanotide (RM-493) on weight and
other factors in patients with pro-opiomelanocortin (POMC) deficiency obesity due to rare
bi-allelic loss-of function POMC or PCSK1 genetic mutations.